Plitidepsin to treat multiple myeloma

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Multiple myeloma (MM) is a hematological malignancy with a 5-year survival rate of 52%.
• Myeloma bone disease, characterized by lytic lesions, causes significant pain and mobility issues in MM patients.
• Existing therapies for relapsed or refractory MM have limitations, necessitating novel treatment approaches.

Purpose of the Study:

• To introduce plitidepsin as a novel therapeutic agent for multiple myeloma (MM).
• To describe the mechanism of action of plitidepsin, focusing on its interaction with elongation factor 1-α 2 (eEF1A2).
• To highlight the approval and clinical utility of plitidepsin in third- and fourth-line MM treatment.

Main Methods:

• The study focuses on the mechanism of action of plitidepsin, a marine-derived compound.
• It details plitidepsin's interaction with elongation factor 1-α 2 (eEF1A2), which is overexpressed in MM cells.
• The research supports the drug's approval and its use in combination therapy.

Main Results:

• Plitidepsin demonstrates anticancer effects by interacting with eEF1A2, targeting its noncanonical role.
• This interaction leads to a proapoptotic response in MM cells.
• Plitidepsin has been approved in Australia for MM patients who have failed or become resistant to prior therapies.

Conclusions:

• Plitidepsin represents a first-in-class drug for treating relapsed or refractory multiple myeloma.
• Its unique mechanism of action provides a new therapeutic option, expanding the anti-MM treatment landscape.
• The combination of plitidepsin and dexamethasone offers a valuable treatment strategy for advanced MM patients.